简介
中山大学附属第六医院副研究员，博士研究生导师。作为第一或通讯作者在JAMA Oncol、J Natl Cancer Inst、Nat Commun、BMC Med、Br J Cancer、J Immunother Cancer、J Natl Compr Canc Netw、Clin Chem等期刊发表SCI论文30余篇，多篇论文被选为封面论文或ESI高被引论文。主持国家自然科学基金3项、广东省自然科学基金3项等多个国家级和省市级科研项目。拥有多项科技应用成果，作为第一发明人获得QASM和MePEC等国家发明专利授权5项，MoRad和MeTIL等软件著作权2项。QASM是入选2021年全国高价值专利项目的15项成果之一。目前为美国癌症研究协会（AACR）会员（Active Member）、Journal of Gene Medicine编委。代表性成果包括：
（1）研发了第三代甲基化特异性PCR技术QASM，实现了在单碱基分辨率下检测基因组甲基化水平 (Clin Chem 2019)，解决了基因组“暗物质”——CpG匮乏区甲基化PCR定量的难题，入选美国临床化学学会年度论文，并在国际上十个著名医疗中心进行了应用，揭示了CpG匮乏区甲基化的肿瘤标志物价值(JNCI 2023；期刊配发同期社评)；
（2）开发了可以定量评估基因组表观遗传信息丢失的方法（BMC Med 2024），并在疾病中追踪生物学衰老进程(Nat Commun 2022；F1000论文,ESI高被引论文)；利用表观遗传信息，开发了可以在细胞类型分辨率下描绘肿瘤免疫微环境的CD8+ MeTIL技术 (J Immunother Cancer 2021)；
（3）系统解析了“炎症衰老-肿瘤进展”中关键的表观遗传重编程事件，揭示了m6A甲基化依赖的ALKBH5/RAB5A信号轴（Clin Transl Med 2023）以及四链体DNA构象转换(iScience 2022)的作用和机制；
（4）针对不同结直肠癌亚型，建立了临床-分子-病理-影像-组学融合的诊断体系（Br J Cancer 2024, JNCCN 2023, Radiother Oncol 2023）；完善了体外诊断标志物的时间特异性应用范式（JNCCN 2022）和去中心化整合研究体系（JAMA Oncol 2019）。
发表论文/著作
1. Zhuang Z#, Lin J#, Wan Z#, Weng J, Yuan Z, Xie Y, Liu Z, Xie P, Mao S, Wang Z, Wang X, Huang M, Luo Y and Yu H*. Radiogenomic profiling of global DNA methylation associated with molecular phenotypes and immune features in glioma. BMC Med 22, 352 (2024).
2. Cai J#, Lin K#, Luo T#, Weng J, Liu H, Yuan Z, Wan Z, Han J, Lin J, Liu X, Wang X, Huang M, Luo Y and Yu H*. Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial. Br J Cancer. 2024 May;130(9):1434-1440.
3. Yu H#, Wang X, Bai L, Tang G, Carter KT, Cui J, Huang P, Liang L, Ding Y, Cai M, Huang M, Liu H, Cao G, Gallinger S, Pai RK, Buchanan DD, Win AK, Newcomb PA, Wang JP*, Grady WM*, Luo Y*. DNA Methylation Profile in CpG-depleted Genomic Region Uncovers an Epigenetic Subtype with High Risk of Recurrence in Early-stage Colorectal Cancer. J Natl Cancer Inst. 2023 Jan 10;115(1):52-61.
4. Shen D#, Lin J#, Xie Y, Zhuang Z, Xu G, Peng S, Tang G, Bai L, Zhu M, Zhang Y, Huang Z, Wang P, Liu X, Huang M, Luo Y*, Wang X*, Yu H*. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner. Clin Transl Med. 2023 May;13(5):e1279.
5. Xie Y#, Lin J#, Zhang N#, Wang X, Wang P, Peng S, Li J, Wu Y, Huang Y, Zhuang Z, Shen D, Zhu M, Liu X, Liu G, Meng X, Huang M, Yu H*, Luo Y*. Prevalent Pseudoprogression and Pseudoresidue in Rectal Cancer Patients Treated with Neoadjuvant Immune Checkpoint Inhibitors. J Natl Compr Canc Netw. 2023 Feb;21(2):133-142.e3.
6. Cao X#, Li W, Wang T, Ran D, Davalos V, Planas-Serra L, Pujol A, Esteller M, Wang X, Yu H*. Accelerated biological aging in COVID-19 patients. Nat Commun. 2022 Apr 19;13(1):2135.
7. Shen D#, Wang X, Wang H, Xu G, Xie Y, Zhuang Z, Huang Z, Li J, Lin J, Wang P, Huang M, Luo Y, Yu H*. Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA. J Natl Compr Canc Netw. 2022 Mar 1:1-10.
8. Zou Q#, Wang X#, Ren D#, Hu B, Tang G, Zhang Y, Huang M, Pai RK, Buchanan DD, Win AK, Newcomb PA, Grady WM, Yu H*, Luo Y*. DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. J Immunother Cancer. 2021;9.
9. Yu H#, Bai L, Tang G, Wang X, Huang M, Cao G, Wang J, Luo Y*. Novel Assay for Quantitative Analysis of DNA Methylation at Single-Base Resolution. Clin Chem. 2019;65:664-673.
10. Yu H#, Luo Y*. Decentered Crowdfunded Clinical Studies-Open a New Era of Medical Research. JAMA Oncol. 2019;5:9-10.
11. Li L#, Xu B#, Zhuang Z#, Li J, Hu Y, Yang H, Wang X, Lin J, Zhou R, Chen W, Ran D, Huang M, Wang D*, Luo Y*, Yu H*. Accurate tumor segmentation and treatment outcome prediction with DeepTOP. Radiother Oncol. 2023 Feb 21;183:109550.
12. Wang X#, Chen S#, Zhao Z, Chen F, Huang Y, Guo X, Lei L, Wang W, Luo Y, Yu H*, Wang J*. Genomic G-quadruplex Folding Triggers a Cytokine-mediated Inflammatory Feedback Loop to Aggravate Inflammatory Diseases. iScience. 2022.
13. Chen Z#, Huang Z#, Luo Y, Zou Q, Bai L, Tang G, Wang X, Cao G, Huang M, Xiang J*, Yu H*. Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer. J Transl Med. 2021;19:73.
14. Xie Y#, Lin J#, Wang X, Wang P, Zhuang Z, Zou Q, Cai D, Huang Z, Bai L, Tang G, Huang M, Wang J, Yu H*, Luo Y*. The Addition of Preoperative Radiation Is Insufficient for Lateral Pelvic Control in a Subgroup of Patients with Low Locally Advanced Rectal Cancer: A Post-Hoc Study of a Randomized Controlled Trial. Dis Colon Rectum. 2021.
15. Zhuang Z#, Liu Z#, Li J#, Wang X, Xie P, Xiong F, Hu J, Meng X, Huang M, Deng Y, Lan P, Yu H*, Luo Y*. Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer. J Transl Med. 2021;19:256.
其他网页
http://www.rig-sysu.org/qnyjy/info_93.aspx?itemid=542
